WSC 2022 | Phase II Endovascular Stroke Treatment Only (ESTO) Trial

Adnan Qureshi, MD, University of Missouri-Columbia, Columbia, MO, discusses the findings of the Phase II ESTO (Endovascular Stroke Treatment Only; NCT04240470) trial. The single arm trial recruited 72 patients with acute ischemic stroke, aiming to determine whether mechanical thrombectomy (MT) alone performed as well as MT in combination with intravenous thrombolysis (IVT). All patients were candidates for both IV thrombolysis and MT and were treated with MT alone. At 3 months post-treatment, the rates of functional independence (modified Rankin score (mRS) 0-2) were much higher in the patients treated with MT alone than if they had received IVT plus MT, based on historical control data. These data suggest that MT alone does not produce worse results than IVT plus MT, adding to the literature base on this debate. Dr Qureshi notes the continued need for new data to address this topic, based on the substantial variability in trial settings. This interview took place at the World Stroke Congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.